TNF and rheumatoid arthritis: In this current study, rather than utilizing a TNF-α antibody approach to capture and clear it before it can potentially reach its target, as is effectively achieved in the treatment of rheumatoid arthritis, the experimental drug 3,6′-dithiothalidomide was employed to reduce TNF-α synthesis [43] and thereby maintain but dramatically lower its physiological release pattern.